Wearable Artificial Kidneys (WAK) will minimise hospital re-admissions and medical expenditure related to hospitalisation and treatment for patients suffering from end stage renal disease (ESRD), according to a new report by GBI Research medical industry experts.
GBI Research's team of industry experts prepared the report using data and information sourced from proprietary databases, primary and secondary research and in-house analysis.
The fully automated, lightweight and waterproof WAK eliminates normal dialysis procedures, which can take up to four hours, three times a week, without restricting lifestyle or diet.
The WAK enables a continuous dialysis treatment option for patients with ESRD by using nanomaterials, such as carbon nanotubes to mimic normal kidney function.
The battery operated WAK also avoids the sudden electrolyte imbalances associated with timed dialysis and recycles bodily fluids to reduce protein loss and eliminate water loss, providing ESRD patients with safer care.
Patients implanted with a WAK showed considerable improvement in quality of life, as treatment requires minimal patient intervention, the research team said.
The report stated that increased use of WAKs will not only lead to financial savings for public health services, but also increase patient confidence and raise the profile of renal dialysis within the world of medical innovations.
Additionally, the report provides information and analysis on the global renal dialysis equipment market, covering the market landscape, competitive landscape and market trends relating to dialysis accessories, continuous renal replacement therapy machines, peritoneal dialysis solutions and hemodialysis machines.
The global renal dialysis equipment market is expected to grow at a compound annual growth rate (CAGR) of six percent, to $12.7bn, during 2010-2017.